VANCOUVER, B.C., August 29, 2025 – PenderFund Capital Management Ltd. (“Pender”) is pleased to announce that as of August 28, 2025 Purpose Investments Inc. (“Purpose”) has assigned the management and trusteeship of Purpose Select Equity Fund to Pender, whereupon it has been renamed Pender Alternative Select Equity Fund (the “Fund”). This transition was approved by unitholders […]
Dear Unitholders, The Pender Alternative Arbitrage Fund and the Pender Alternative Arbitrage Plus Fund were up 0.6% and 0.9%[1] respectively in July 2025 while the HFRI ED: Merger Arbitrage Index (USD) returned 1.1%[2]. Portfolio Update July saw another positive month of performance in the Fund as several key holdings achieved all required regulatory approvals and […]
VANCOUVER, B.C. (TSXV: PTF) Pender Growth Fund Inc. (the “Company”) today announced its financial and operational results for the three months and six months ended June 30, 2025. Financial Highlights Net income was $8,742,446 for the three months ended June 30, 2025 (June 30, 2024 – net income $22,533,335) due to positive investment performance in the […]
Highlights Modine Manufacturing Company (MOD) and Rambus Inc. (RMBS) were top contributors while Molina Healthcare Inc. (MOH) was a top detractor to performance in the month of July 2025. The S&P MidCap 400 Index posted total returns of 1.6% for the month of July 2025, underperforming its large cap peer, the S&P 500 Index, […]
Dear Unitholders, The Pender Alternative Absolute Return Fund returned 0.3%[1] in July, bringing year-to-date returns to 1.0%. Credit markets saw tighter spreads in July and positive absolute returns, but by late in the month there were signs of exhaustion as historically expensive spread levels were met with mixed earnings from cyclical market segments and significant […]
The Pender Corporate Bond Fund enjoyed a profitable July, returning 1.5%[1]. The good result was due to a number of holding-specific catalyst events that allowed the Fund to outperform benchmarks. One key contributor for the period was our stake in the capital structure of Esperion Therapeutics Inc. Management’s successful efforts in extending the cholesterol-lowering drug […]
"*" indicates required fields
